Analyzing CDT Equity (NASDAQ:CDT) and Chugai Pharmaceutical (OTCMKTS:CHGCY)

CDT Equity (NASDAQ:CDT) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Profitability

This table compares CDT Equity and Chugai Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	N/A	-350.23%
Chugai Pharmaceutical	33.08%	20.80%	18.17%

Valuation & Earnings

This table compares CDT Equity and Chugai Pharmaceutical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$17.80 million	($3,479.96)	0.00
Chugai Pharmaceutical	$7.74 billion	9.98	$2.56 billion	$0.79	29.72

Chugai Pharmaceutical has higher revenue and earnings than CDT Equity. CDT Equity is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for CDT Equity and Chugai Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1	0	0	0	1.00
Chugai Pharmaceutical	0	0	0	0	0.00

Risk & Volatility

CDT Equity has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are owned by institutional investors. 7.7% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Chugai Pharmaceutical beats CDT Equity on 7 of the 11 factors compared between the two stocks.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.